Trial Profile
A Study of the Effects of Dapagliflozin on Ambulatory Aortic Pressure, Arterial Stiffness and Urine Albumin Excretion in Patients With Type 2 Diabetes
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- 14 Apr 2021 Results assessing the effects of dapagliflozin on ambulatory blood pressure (BP) levels and arterial stiffness parameters in patients with type-2 diabetes mellitus, presented at the Joint Meeting of the European Society of Hypertension and International Society of Hypertension.
- 05 Dec 2020 Results of secondary analysis assessing effects of Dapagliflozin on short-term blood pressure variability in patients with T2DM published in the American Journal of Hypertension
- 30 Nov 2019 Status changed from recruiting to discontinued.